MedTrace Logo

Probiotic on Type 2 Diabetes and Chronic Obstruction Pulmonary Disease

NCT05492448 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-02-27

No results posted yet for this study

Summary

This trial is a randomized, double-blind, parallel placebo clinical trial, the purpose of which is to investigate whether the adjuvant therapy of using probiotics during the treatment of diabetic patients can decrease blood sugar levels significantly in comparison with placebo, and observe if the reduced lung function could be recovered in patients with type 2 diabetes (T2DM) and chronic obstructive pulmonary disease (COPD) simultaneously.

Conditions

Interventions

DIETARY_SUPPLEMENT

Placebo

Subjects take one pack containing maltodextrin twice daily after breakfast and dinner.

DIETARY_SUPPLEMENT

L. salivarius AP-32 and L. reuteri GL-104

Subjects take one pack containing L. salivarius AP-32 and L. reuteri GL-104 twice daily after breakfast and dinner.

DIETARY_SUPPLEMENT

L. reuteri GL-104

Subjects take one pack containing L. reuteri GL-104 twice daily after breakfast and dinner.

Sponsors & Collaborators

  • Glac Biotech Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-19
Primary Completion
2025-08-15
Completion
2025-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05492448 on ClinicalTrials.gov